SLC39A6 and breast carcinoma: In summary, we have explored the relevance of both ZIP7 and ZIP6 as therapeutic targets in anti- hormone resistant breast cancers, with both our in vitro studies and examination of clinical data highlighting the potential of their targeting in the context of tamoxifen resistance.